Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

yahoo.com - Faheem Tahir - Merck & Co. (MRK) to Acquire Terns Pharma for $6.7 Billion
Merck & Co. (MRK) to Acquire Terns Pharma for $6.7 Billion
Yahoo!

Merck & Co., Inc. (NYSE: MRK) is included in our list of the best stocks to buy for financial stability. On March 25, 2026, Merck & Co., Inc. (NYSE:MRK) came into the limelight when Reuters reported that the company had agreed to buy Terns Pharma…

afr.com - Michael Smith - Pharma giants slam 'appalling' postcode lottery for weight loss drugs
Pharma giants slam 'appalling' postcode lottery for weight loss drugs
Australian Financial Review

Global pharmaceutical giants stepped up pressure on the Albanese government to subsidise weight-loss drugs, releasing data showing people in Sydney's west and regional areas are 34 per cent less likely to buy the medicines than affluent city…

marketbeat.com - Eastern Bank Acquires 263,867 Shares of Royalty Pharma PLC $RPRX
Eastern Bank Acquires 263,867 Shares of Royalty Pharma PLC $RPRX
MarketBeat

Eastern Bank lifted its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 71.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 635,122 shares of…

marketbeat.com - Urogen Pharma $URGN Shares Acquired by JPMorgan Chase & Co.
Urogen Pharma $URGN Shares Acquired by JPMorgan Chase & Co.
MarketBeat

JPMorgan Chase & Co. raised its stake in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 36.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 534,545…

marketbeat.com - Wedge Capital Management L L P NC Lowers Stock Position in Royalty Pharma PLC $RPRX
Wedge Capital Management L L P NC Lowers Stock Position in Royalty Pharma PLC $RPRX
MarketBeat

Wedge Capital Management L L P NC decreased its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 12.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The…

express.co.uk - Ciaran McGrath - UK just 'a few weeks' from medicine shortages
UK just 'a few weeks' from medicine shortages
Express.co.uk

Medicine shortages could be looming, experts have warned Britain is teetering on the brink of full-blown medicine shortages, with everything from painkillers to critical cancer treatments likely to be in short supply if the war with Iran drags on…

thehindubusinessline.com - DSP Healthcare: Playing It Safe
DSP Healthcare: Playing It Safe
BusinessLine

The US-Iran conflict has impacted every segment of the equity market in the last three weeks including the healthcare sector, BSE Healthcare and Nifty Pharma nonetheless. Compared to 11 per cent decline year-to-date in Nifty 50, BSE Healthcare has…

fool.com - Thomas Niel - 1 Reason This Biotech Stock Could Triple Before Year-End
1 Reason This Biotech Stock Could Triple Before Year-End
The Motley Fool

When you think of GLP-1s and investing, the two large pharmaceutical companies benefiting most from this trend may first come to mind. First, there's Novo Nordisk, the first to bring GLP-1 weight loss drugs to market, with Ozempic and Wegovy.

foxnews.com - Alan Wilson - SOUTH CAROLINA AG WILSON: Fentanyl is a national security threat - follow the Chinese money
SOUTH CAROLINA AG WILSON: Fentanyl is a national security threat - follow the Chinese money
Fox News

Every day, families across this country are losing loved ones to fentanyl. This is not just a public safety crisis. It is not just a public health emergency. It is something far more dangerous. It is a national security threat. As attorneys…

thehindubusinessline.com - Crude oil shock deepens market jitters as Hormuz crisis hits India's macro outlook
Crude oil shock deepens market jitters as Hormuz crisis hits India's macro outlook
BusinessLine

Equity markets are grappling with a deepening correction as a geopolitical shock in West Asia morphs into a full-blown oil-driven macro risk. What began as a sentiment-led sell-off has now evolved into a tangible supply disruption, with tanker…

dailymail.co.uk - John Lee - 20 years for a cycle path? All we get is excuses, not infrastructure
20 years for a cycle path? All we get is excuses, not infrastructure
Mail Online

There is an innovative and fervently awaited greenway project near where I live that has been inexplicably delayed for years now. When I say the delays are inexplicable, the many State agencies who take some – never all – the…

247wallst.com - Michael Williams - PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026
PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026
24/7 Wall St

VanEck Pharmaceutical ETF (PPH) is 17.91% concentrated in Eli Lilly (LLY), which has fallen 16% year-to-date as generic GLP-1 competition and patent expirations in emerging markets threaten pricing power, while Novartis (NVS) holds 11.23% and Merck…

thehindubusinessline.com - Bandu's Blockbusters For March 29, 2026
Bandu's Blockbusters For March 29, 2026
BusinessLine

On April 1, four years ago, piqued by the incessant jokes in the village at his expense, Bandu Barve decided he'd had enough. It was time for him to turn ‘smart'. His dead granny's voice rang in his ears — “Read the papers…

cyprus-mail.com - A forage through the fields of Cyprus
A forage through the fields of Cyprus
Cyprus Mail

Mastic and mustard, sea squill and agave and cistus and meadow crane's-bill. “This is chickweed,” says Katie Richards, pointing out a thin leafy plant. “This one is chickweed. Let me take a picture of it, just to…

marketbeat.com - Syquant Capital Sas Purchases Shares of 71,000 Eli Lilly and Company $LLY
Syquant Capital Sas Purchases Shares of 71,000 Eli Lilly and Company $LLY
MarketBeat

Syquant Capital Sas purchased a new position in Eli Lilly and Company (NYSE:LLY - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 71,000 shares…

Receive a Daily briefing on Pharma Industry News

Get Started